Skip to content

IMMUNIS

Active Private limited companyfounded 2006active for 20 yearsKaperberg 7, 4700 EupenKBO/BCE: BE 0883.690.091

Lifetime

19 annual accounts with figures on one time axis
peak of €638,777 in 2024
€617,428▼ 3.3%
lowest -€2,070 in 2007
€452,174▼ 7.9%
peak of €33,637 in 2019
€6,161▲ 0.6%
€1.0m▲ 11.3%
peak of 2.9 FTE in 2012
2.5 FTEunchanged
Board6 names since 2017
5 directors and 4 others
Documentsfilings and deeds
11-05-202681 days before the deadline
2025financial year
resigns as director 10-12

Key points

from the 2025 annual accounts

Equity

€6,161 ▲ 0.6%

IMMUNIS has made a profit without a break since 2009.

Debts

€1.0m 99% of the balance sheet
Financial debts 33%Suppliers 16%Taxes and wages 5%Other 46%

Of this, €695,029 falls due within a year.

Position in the sector

€6,161

Less equity than 93% of companies in legal and accounting. Sector median €222,994 · 807 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 934 companies had the same profile as IMMUNIS has now. Each dot stands for 3 companies, two years later.

92.9%
were still trading
4.8%
stopped another way
1.9%
went bankrupt
  • Micro
  • 20 years or older
  • solvency under 10%
  • a profit of 5% of the balance sheet or more

Another 0.3% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 934 companies, not a prediction for IMMUNIS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director,
Director,
Director,
Director, , since 24-01-2023
Director,
Board & ownership

Recent changes

resigns as director acts as permanent representative · General meeting of 24-10-2025 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0883690091
appointed as director acts as permanent representative · General meeting of 24-01-2023 · Gazette deed
resigns as director Director discharge: · General meeting of 15-12-2022 · Gazette deed
All 29 events

Comparable companies

same main activity, similar in size and age
Company
IMMUNIS Eupen €1.0m €617,428 0.6% 2.5
Adviesbureau ABL Landen €1.2m €689,121 90.3% 3.3
WM CONSULTING Deinze €1.2m €571,354 78.3% 3
Verbanck, Plas & Partners Ghent €0.8m €498,603 12.2% 3.3
ACCOUNTANTSKANTOOR DEFACTO Brasschaat €1.3m €732,036 72.8% 2.1
MALMENDIER & ASSOCIES Visé €1.4m €760,663 92.6% 4.4
VBW ACCOUNTANTS Kalmthout €0.8m €506,279 4.8% 3.6

These companies have the same main activity as IMMUNIS: certified accountants and tax accountants (NACE 69201). They are comparable in size and age: total assets between €773,000 and €1.4m, founded between 1999 and 2009.

Official details

Source: KBO
Status
Active since 21-09-2006Normal situation
Activity
Certified accountants and tax accountantsNACE 69201
Joint committee
336Liberal professions · annual accounts 2025
Establishment unit
2.161.459.0174700 Eupen, since 21-09-2006
Financial year end
31 December
Peppol
Reachable since 09-10-2025
Company details

Annual accounts 2025

≈ €1.1mestimated
€1.0m▲ 11.2%
Employeeson 31-12-2025
3=
Filing
Filed on 11-05-2026, 81 days before the end of the filing period
Financials

Insights on IMMUNIS

IMMUNIS has existed since 2006. In 2009 the gross margin rose from €9,615 to €187,371 and staff from 1 to 1.4 full-time equivalents.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about IMMUNIS

What is the company number of IMMUNIS?
The company number of IMMUNIS is 0883.690.091. The VAT number is the same number with BE in front: BE 0883.690.091.
Where is IMMUNIS based?
The registered office is at Kaperberg 7, 4700 Eupen.Company details
What does IMMUNIS do?
According to the KBO register, the main activity is certified accountants and tax accountants (NACE 69201).
What is the legal form of IMMUNIS?
IMMUNIS is a private limited company (BV).
When was IMMUNIS founded?
IMMUNIS was founded on 21-09-2006.
Is IMMUNIS still active?
Yes, IMMUNIS is an active enterprise in the KBO register.
How many employees does IMMUNIS have?
IMMUNIS had an average of 2.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does IMMUNIS fall under?
In its 2025 annual accounts, IMMUNIS states joint committee 336 (Liberal professions).
What is the turnover of IMMUNIS?
The turnover in financial year 2025 is ≈ €1.1m. This figure is estimated from the gross margin of €617,428 and 34 comparable companies (NACE 69201). It probably lies between €930,000 and €1.3m.
Is IMMUNIS profitable?
In financial year 2025, IMMUNIS made a profit of €452,174.
Where can I find the annual accounts of IMMUNIS?
IMMUNIS filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of IMMUNIS due?
IMMUNIS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.